Sarcoma
Conditions
Keywords
Sarcoma, Hydroxychloroquine, Sirolimus, PET
Brief summary
Determine the objective response rate in sarcoma patients treated with hydroxychloroquine and sirolimus.
Detailed description
This study evaluates the daily morning single dose of hydroxychloroquine /sirolimus combined therapy in sarcoma patients. Study arm were treated with hydroxychloroquine 400 mg /sirolimus 2mg gd for 8-wk therapy. Patients will be discontinued from the study after 8-wk observation period. Patients must meet all of the following inclusion criteria to be eligible for enrollment into the study. TREATMENT PLAN: 1. Both hydroxychloroquine 200 mg/tab and sirolimus 1 mg/tab are pills each are taken 2 tablet orally every day. Treatment will be divided into time periods called cycles. Each treatment cycle is 28 days. The exception to this 28 day cycle is when participants start taking the pills for the first time. When the hydroxychloroquine and sirolimus begins, the first cycle of 28 days begins. 2. There are several tests and procedures that will be performed at specific time periods during protocol treatment. These include: blood work, performance status assessment, questions about medical history and medications, tumor assessment with PET/CT or MRI and, eye exams. 3. Dose modification criteria: Participants may continue to receive study treatment as long as they experienced grade 1 or 2 side effects. The treatment drug will be 50% reduction of dose in any grade 3 toxicity; and discontinued of treatment (off-study) in any grade 4 toxicity or disease progression during treatment.
Interventions
DRUGSirolimus and hydroxychloroquine
Both hydroxychloroquine 200 mg/tab and sirolimus 1 mg/tab are pills each are taken 2 tablet orally QD for 2 cycles . Each treatment cycle is 28 days.
Sponsors
Shin Kong Wu Ho-Su Memorial Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
21 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients with Soft tissue sarcoma (including high grade or low grade soft tissue sarcoma、osteogenic sarcoma and the following 4 recurrent benign tumors which may have aggressive clinical course after initial surgical treatment : lymphangioleiomyomatosis、angiomyolipoma、giant cell tumor、phylloid tumor) that are refractory to at least first line full course of standard chemotherapy, relapsed after standard chemotherapy, or who have no standard therapy available and refused chemotherapy * Patients must be \>/= 21 years. * Patients must be \>/= 4 weeks beyond treatment with a cytotoxic chemotherapy regimen, or therapeutic radiation, or major surgery. Patients may have received palliative localized radiation immediately before or during treatment provided that radiation is not delivered to the only site of disease being treated under this protocol. For biologic/targeted agents patients must be \>/= 5 half-lives or \>/= 3 weeks form the last dose (whichever comes first). * Eastern Cooperative Oncology Group(ECOG) performance status \</= 2 * Patients must have certain organ and marrow function resave defined as: White blood cell(WBC\_ \>/= 3,000/mL;platelets \>/=100,000/mL; creatinine \</= 2 X Upper Limit of Normal (ULN); total bilirubin \</= 2.0; Alanine Aminotransferase(ALT;SGPT) \</= 5 X ULN; Exception for patients with liver metastasis: total bilirubin \</= 3 x ULN; ALT(SGPT) \</= 8 X ULN;cholesterol \</= 350 mg/dL; triglycerides \</= 400 mg/dL (sirolimus and hydroxychloroquine only). * Patients must be able to understand and be willing to sign a written informed consent document.
Exclusion criteria
* Uncontrolled intercurrent illness, including, but not limited to, uncontrolled infection, uncontrolled asthma, need for hemodialysis, need for ventilatory support. * Pregnant or lactating women. * History of hypersensitivity to sirolimus. * History of hypersensitivity to hydroxychloroquine * Patients unwilling or unable to sign informed consent document.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Maximum Standardized Uptake Values (SUVmax) Change on PET/CT Scan | 2 Weeks | A baseline whole-body \[18F\]-fluorodeoxyglucose(FDG) PET was performed before therapy initiation. Patients received 1 mg of Rapa and 200 mg of HCQ twice a day before a meal for 2 weeks. A second \[18F\]-FDG PET was performed after treatment completion. SUVs were calculated for all lesions. Regions of interest (ROI) were contoured to represent tumors (\>2 cm) and organs (lungs, spleen, and liver) on all transaxial and coronal slices. ROIs were normalized for injection dose and body weight, and the maximum voxel value was recorded for each region or organ. The highest SUV measured with increased uptake was considered the SUVmax. Correlative diagnostic CT examinations were used for accurate localization of the lesions. The most intense uptake at baseline was identified as the index lesion and evaluated for treatment response. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The Toxicity | 2 Weeks | Number of Participants with Adverse Events. Toxicities parameters are according to the Nation Cancer Institute Common Terminology Criteria for Adverse Event, version 3.0. |
Countries
Taiwan
Participant flow
Recruitment details
Subjects were enrolled between August 2012 and June 2014 at Department of Radiation Therapy and Oncology, Shin Kong Wu Ho-Su Memorial Hospital.
Participants by arm
| Arm | Count |
|---|---|
| Sirolimus and Hydroxychloroquine Patients received 1 mg of Rapa and 200 mg of HCQ twice a day before a meal for 2 weeks. | 10 |
| Total | 10 |
Baseline characteristics
| Characteristic | Sirolimus and Hydroxychloroquine |
|---|---|
| Age, Continuous | 63 years |
| Sex: Female, Male Female | 5 Participants |
| Sex: Female, Male Male | 5 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 3 / 10 |
| serious Total, serious adverse events | 0 / 10 |
Outcome results
Primary
The Maximum Standardized Uptake Values (SUVmax) Change on PET/CT Scan
A baseline whole-body \[18F\]-fluorodeoxyglucose(FDG) PET was performed before therapy initiation. Patients received 1 mg of Rapa and 200 mg of HCQ twice a day before a meal for 2 weeks. A second \[18F\]-FDG PET was performed after treatment completion. SUVs were calculated for all lesions. Regions of interest (ROI) were contoured to represent tumors (\>2 cm) and organs (lungs, spleen, and liver) on all transaxial and coronal slices. ROIs were normalized for injection dose and body weight, and the maximum voxel value was recorded for each region or organ. The highest SUV measured with increased uptake was considered the SUVmax. Correlative diagnostic CT examinations were used for accurate localization of the lesions. The most intense uptake at baseline was identified as the index lesion and evaluated for treatment response.
Time frame: 2 Weeks
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Sirolimus and Hydroxychloroquine | The Maximum Standardized Uptake Values (SUVmax) Change on PET/CT Scan | -19.6 percentage of the SUVmax Change |
Secondary
The Toxicity
Number of Participants with Adverse Events. Toxicities parameters are according to the Nation Cancer Institute Common Terminology Criteria for Adverse Event, version 3.0.
Time frame: 2 Weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Sirolimus and Hydroxychloroquine | The Toxicity | 3 participants |